GS Capsule Forms Strategic Partnership with BioDuro-Sundia
GS Capsule Forms Strategic Partnership with BioDuro-Sundia
Shanghai, June 19, 2023 –GS and BioDuro-Sundia Capsule held a Strategic Partnership signing ceremony today in the Shanghai New International Expo Center during CPHI China. The two parties will focus on areas including formulation technology innovation and packaging material quality improvement to strengthen the development of cornerstone capabilities through strategic cooperation.
Mr. Michael Zhu, CEO of GS Capsule and Dr. Kent Payne, CEO of BioDuro-Sundia, attended the signing ceremony.
Mr. Michael Zhu, GS Capsule CEO, said: "We firmly believe that today's signing ceremony marks the beginning of complementary advantage, information sharing and mutual benefit for both parties. We will strive to build a new platform and mechanism for cooperation and development between the two parties, and improve the level of synergy, enhance innovation ability, and achieve new strides in strategic development."
Dr. Kent Payne, BioDuro-Sundia CEO, said: “GS Capsule and BioDuro-Sundia are both Advent International portfolio companies and have shared values. BioDuro-Sundia is committed to collaborating with pharma and biotech companies to discover and accelerate life-saving medicines for millions of patients worldwide. We believe that working together will strengthen our ability to provide solutions for our clients.”
About GS Capsule
GS Capsule was established in 1983 with over forty years of capsule industry expertise in our world class manufacturing facilities. GS Capsules is a premier global empty hard capsule manufacturer producing Gelatin, HPMC, Pullulan and Enteric Coated capsules. We offer 13 different capsule sizes ranging from 000# to 5, elongated versions, clinical trial applications and a wide range of customized color options. Currently, GS Capsule is the largest empty capsule manufacturer in China with 48+ billion capsule production capacity.
About BioDuro-Sundia
BioDuro-Sundia, an Advent International portfolio company, is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 10 global sites across 7 cities.
Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Our science-driven, customer-oriented, people-focused culture enables us to provide top-tier integrated, fast, and flexible tailored services to our customers, to meet their unique needs and accelerate development timelines.